Biotech | September 21, 2021
HUTCHMED initiates a Japan bridging study to Support Surufatinib
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year
MeMed BV is a first-of-its-kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes
Clindamycin Phosphate Foam, 1% is the generic version of Evoclin Foam, 1%
If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
It approves tissue-based NGS companion diagnostic for Takeda's targeted therapy for NSCLC patients with EGFR Exon20 insertion mutations
The pharma park will be built at an estimated cost of Rs 34.94 crore and will be spread over 50 acres at Chanho close to Ranchi
The document is a global recommendation for circular packaging design. It will be updated and adapted to changes in the collection, sorting and recycling technology, as well as to future material development
Packaged junk food which is a major component of unhealthy diets is responsible for more deaths worldwide than any other risk factor
Subscribe To Our Newsletter & Stay Updated
